Zenas BioPharma, Inc. (ZBIO)
29.53
+1.27
(+4.49%)
USD |
NASDAQ |
Nov 09, 14:42
Zenas BioPharma Total Liabilities (Quarterly) : 462.91M for Sept. 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 462.91M |
| June 30, 2026 | 454.59M |
| March 31, 2026 | 411.85M |
| December 31, 2025 | 141.50M |
| September 30, 2025 | 125.59M |
| June 30, 2025 | 53.46M |
| Date | Value |
|---|---|
| March 31, 2025 | 49.45M |
| December 31, 2024 | 57.51M |
| September 30, 2024 | 44.00M |
| June 30, 2024 | 39.12M |
| March 31, 2024 | 51.46M |
| December 31, 2023 | 43.82M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 406.66M |
| Alnylam Pharmaceuticals, Inc. | 4.391B |
| Anika Therapeutics, Inc. | 52.02M |
| Savara, Inc. | 48.48M |
| Vericel Corp. | 132.94M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 675.22M |
| Shareholders Equity (Quarterly) | 212.31M |
| Debt to Equity Ratio | 1.884 |
| Current Ratio | 9.422 |
| Net Debt Paydown Yield | -4.37% |